• Je něco špatně v tomto záznamu ?

Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives

J. Guillon, A. Cohen, C. Boudot, A. Valle, V. Milano, RN. Das, A. Guédin, S. Moreau, L. Ronga, S. Savrimoutou, M. Demourgues, E. Reviriego, S. Rubio, S. Ferriez, P. Agnamey, C. Pauc, S. Moukha, P. Dozolme, SD. Nascimento, P. Laumaillé, A....

. 2020 ; 35 (1) : 432-459. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005593

A series of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline, and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives was designed, synthesised, and evaluated in vitro against three protozoan parasites (Plasmodium falciparum, Leishmania donovani, and Trypanosoma brucei brucei). Biological results showed antiprotozoal activity with IC50 values in the µM range. In addition, the in vitro cytotoxicity of these original molecules was assessed with human HepG2 cells. The quinoline 1c was identified as the most potent antimalarial candidate with a ratio of cytotoxic to antiparasitic activities of 97 against the P. falciparum CQ-sensitive strain 3D7. The quinazoline 3h was also identified as the most potent trypanosomal candidate with a selectivity index (SI) of 43 on T. brucei brucei strain. Moreover, as the telomeres of the parasites P. falciparum and Trypanosoma are possible targets of this kind of nitrogen heterocyclic compounds, we have also investigated stabilisation of the Plasmodium and Trypanosoma telomeric G-quadruplexes by our best compounds through FRET melting assays.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005593
003      
CZ-PrNML
005      
20200525100952.0
007      
ta
008      
200511s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14756366.2019.1706502 $2 doi
035    __
$a (PubMed)31899980
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Guillon, Jean $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
245    10
$a Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives / $c J. Guillon, A. Cohen, C. Boudot, A. Valle, V. Milano, RN. Das, A. Guédin, S. Moreau, L. Ronga, S. Savrimoutou, M. Demourgues, E. Reviriego, S. Rubio, S. Ferriez, P. Agnamey, C. Pauc, S. Moukha, P. Dozolme, SD. Nascimento, P. Laumaillé, A. Bouchut, N. Azas, JL. Mergny, C. Mullié, P. Sonnet, B. Courtioux,
520    9_
$a A series of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline, and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives was designed, synthesised, and evaluated in vitro against three protozoan parasites (Plasmodium falciparum, Leishmania donovani, and Trypanosoma brucei brucei). Biological results showed antiprotozoal activity with IC50 values in the µM range. In addition, the in vitro cytotoxicity of these original molecules was assessed with human HepG2 cells. The quinoline 1c was identified as the most potent antimalarial candidate with a ratio of cytotoxic to antiparasitic activities of 97 against the P. falciparum CQ-sensitive strain 3D7. The quinazoline 3h was also identified as the most potent trypanosomal candidate with a selectivity index (SI) of 43 on T. brucei brucei strain. Moreover, as the telomeres of the parasites P. falciparum and Trypanosoma are possible targets of this kind of nitrogen heterocyclic compounds, we have also investigated stabilisation of the Plasmodium and Trypanosoma telomeric G-quadruplexes by our best compounds through FRET melting assays.
650    _2
$a antiprotozoální látky $x chemická syntéza $x chemie $x farmakologie $7 D000981
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a Leishmania donovani $x účinky léků $7 D007893
650    _2
$a Plasmodium falciparum $x účinky léků $7 D010963
650    _2
$a chinoliny $x chemická syntéza $x chemie $x farmakologie $7 D011804
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a Trypanosoma brucei brucei $x účinky léků $7 D014346
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cohen, Anita $u IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille, France.
700    1_
$a Boudot, Clotilde $u INSERM U1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, France.
700    1_
$a Valle, Alessandra $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Milano, Vittoria $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Das, Rabindra Nath $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Guédin, Aurore $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Moreau, Stéphane $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Ronga, Luisa $u PREM UMR5254 - UPPA/CNRS, Technopole Hélioparc, Université de Pau, Pau, France.
700    1_
$a Savrimoutou, Solène $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Demourgues, Maxime $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Reviriego, Elodie $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Rubio, Sandra $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Ferriez, Sandie $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
700    1_
$a Agnamey, Patrice $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Pauc, Cécile $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Moukha, Serge $u Université de Bordeaux, Laboratoire de Toxicologie et d'Hygiène Appliquée - INRA, UFR des Sciences Pharmaceutiques, Bordeaux, France.
700    1_
$a Dozolme, Pascale $u Université de Bordeaux, Laboratoire de Toxicologie et d'Hygiène Appliquée - INRA, UFR des Sciences Pharmaceutiques, Bordeaux, France.
700    1_
$a Nascimento, Sophie Da $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Laumaillé, Pierre $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Bouchut, Anne $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Azas, Nadine $u IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille, France.
700    1_
$a Mergny, Jean-Louis $u INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France. Institut Curie, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, Université Paris-Saclay, Orsay, France. Institute of Biophysics of the CAS, Brno, Czech Republic.
700    1_
$a Mullié, Catherine $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Sonnet, Pascal $u UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,France.
700    1_
$a Courtioux, Bertrand $u INSERM U1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, France.
773    0_
$w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 35, č. 1 (2020), s. 432-459
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31899980 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525100952 $b ABA008
999    __
$a ok $b bmc $g 1524451 $s 1095649
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 35 $c 1 $d 432-459 $e - $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace